Oxprenolol: clinical experiences with a new beta-adrenergic blocking drug

An Assessment of the Anti-Anginal Effect of Tolamolol, a New Beta-Blocking Agent

The anti-anginal activity of a new beta-blocking agent, tolamolol, was investigated in an open study.

Seventeen patients ( fourteen males, three females) from two centres were given tolamolol in doses varying from 150 mg to 800 mg daily for periods of between one and thirty-four weeks. Records were made of the number of attacks of angina and of the consumption of sublingual glyceryl trinitrate ( GTN). Blood pressure and heart rate were monitored together with possible side-effects and the results of routine laboratory tests. There was an over-all reduction in anginal attack rates and the number of GTN tablets used, although these did not reach statistical significance in the small numbers concerned. Heart rate and blood pressure were similarly reduced. Side-effects were of mild severity and were tolerated or disappeared with continued treatment.

A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris

A double-blind placebo controlled study of angina pectoris with penbutolol was undertaken in parallel groups in fifty-two patients. The duration of the study was six weeks. The dosage range for penbutolol was 8 mg to 50 mg per day. Six patients were dropped from the analysis. Seventeen patients (81%) in the penbutolol series exhibited a 50% reduction in anginal attacks, NTG consumption and subjective improvement. Significant reduction in nitrite intake was observed. Effort tolerance was improved significantly in those receiving penbutolol. Penbutolol was well-tolerated.

Action of several -adrenoceptor blocking drugs in the pregnant sheep and foetus

1. The effect of several beta-adrenoceptor blocking drugs on the pregnant ewe and foetus were studied. Bunolol, butidrine, oxprenolol, propranolol and USVP65-24 all crossed the ovine placenta and produced a beta-adrenoceptor blockade in the ovine foetus. AH3474, AY21011 and sotalol did not cross the ovine placenta as assessed by the absence of a beta-blockade in the foetus when these compounds were administered to the pregnant ewe.2. Of the beta-blocking compounds tested, only propranolol and oxprenolol produced a prolonged blockade in the foetus. The beta-blockade with propranolol was of 3 h duration in the ewe and 10 h duration in the foetus. Oxprenolol produced a beta-blockade of 3 h duration in the ewe and 8 h in the foetus.3. The beta-blocking drugs which did cross the ovine placenta were more soluble in organic solvents (ether, chloroform, corn oil and olive oil) than those which did not cross the ovine placenta.